DHR · News · 20261022N
Revenue Performance and Mix
DANAHER CORP /DE/ · 2026-10-22 · Importance 42 · Surprise 14 · No source text
Danaher reported third-quarter 2026 revenue of $6.55 billion, up 8.3% year over year and approximately in line with the $6.56 billion analyst estimate. Organic revenue increased 3% year over year, indicating that acquisitions or other non-organic factors contributed to reported growth. Analysts cited improving demand in life-science tools and diagnostics, while bioprocessing remained an area of concern. Stifel projected more than 5% organic growth ahead, driven by Cytiva.
Key facts
- Q3 2026 revenue: $6.55 billion, up 8.3% year-on-year source
- Q3 2026 revenue vs analyst estimates: $6.55 billion reported vs $6.56 billion estimate source
- Another report described Q3 2026 revenue as roughly $6.6 billion source
- Q3 2026 organic revenue rose 3% year on year source
- Market capitalization as of the report: $164.4 billion source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +7.7% | Q3 2026 revenue: $6.55 billion, up 8.3% year-on-year |
| operating_income | positive | realized | +1.5% | Q3 2026 revenue: $6.55 billion, up 8.3% year-on-year |